Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.72 |
| ▸ | KDR | P35968 | 11/20 | 0.63 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3740944 | 0.92 | SRC (0.83) | SRCKDREGFR | |
| SCHEMBL3282493 | 0.83 | SRC (1.00) | SRCKDR | |
| SCHEMBL3192521 | 0.82 | SRC (0.95) | SRCKDR | |
| SCHEMBL3276140 | 0.81 | SRC (0.86) | SRCKDR | |
| SCHEMBL3283205 | 0.79 | SRC (0.84) | SRCKDR | |
| SCHEMBL3281905 | 0.78 | SRC (1.00) | SRCKDR | |
| SCHEMBL3200998 | 0.76 | SRC (1.00) | SRCKDREGFR | |
| SCHEMBL27592195 | 0.75 | EGFR (0.59) | SRCKDREGFR | |
| SCHEMBL3196301 | 0.75 | SRC (1.00) | SRCKDREGFR | |
| SCHEMBL6975385 | 0.74 | SRC (0.77) | SRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | SRC 3241/4885KDR 4015/4885EGFR 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.